Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: Is there an evidence base?

Health Policy and Planning

Volumn 18, Issue 1, 2003, Pages 4-17

  Walker, Damian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost; Cost effectiveness; Evidence base; HIV AIDS; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANTIBODY SCREENING; ARTIFICIAL MILK; ASIA; BLOOD TRANSFUSION; BREAST FEEDING; CALCULATION; CESAREAN SECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONDOM; COST EFFECTIVENESS ANALYSIS; COUNSELING; DECISION MAKING; DEVELOPING COUNTRY; DISEASE TRANSMISSION; EPIDEMIC; EUROPE; EVIDENCE BASED MEDICINE; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MARKETING; MASS MEDIUM; MASS SCREENING; MATHEMATICAL MODEL; MEDICAL DOCUMENTATION; OUTCOMES RESEARCH; RELIABILITY; REVIEW; RISK FACTOR; SEXUAL EDUCATION; SEXUALLY TRANSMITTED DISEASE; SOUTH AND CENTRAL AMERICA; TECHNIQUE; VALIDATION PROCESS; VITAMIN SUPPLEMENTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS SERODIAGNOSIS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV SEROPREVALENCE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTIVE HEALTH SERVICES; SEXUALLY TRANSMITTED DISEASES; SOCIAL MARKETING;

EID: 0037373812     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/18.1.4     Document Type: Review

References (76)

1. World Health Organization. 1999. The World Health Organization Report 1999. Geneva: WHO.
2. UNAIDS. 2000. Report on the Global HIV/AIDs Epidemic. Geneva: UNAIDS.
3. UNAIDS. 1998. AIDS Epidemic Update: December 1998. Geneva: UNAIDS.
4. Merson MH, Dayton JM, O'Reilly K. 2000. Effectiveness of HIV prevention interventions in developing countries. AIDS 14 (Suppl 2): S68-84.
5. Kumaranayake L, Watts C. 2000. Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa. AIDS 14 (Suppl 3): S239-52.
6. Kahn JG, Marseille E. 2000. Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 14: 2609-10.
7. Soderlund N, Lavis J, Broomberg J, Mills A. 1993. The costs of HIV prevention strategies in developing countries. Bulletin of the World Health Organization 71: 595-604.
8. Schrappe M, Lauterbach K. 1998. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS 12 (Suppl A): S231-8.
9. Holtgrave DR, Qualls NL, Graham JD. 1996. Economic evaluation of HIV prevention programs. Annual Review of Public Health 17: 467-88.
10. Beal R, Brunger W, Delaporte E et al. 1992. Safe blood in developing countries: a Report of the EEC's Expert Meeting. Brussels: EEC AIDS Task Force.
11. Kumaranayake L, Pepperall J, Goodman H, Mills A, Walker D. 2000. Costing guidelines for HIV/AIDS prevention strategies. Geneva: UNAIDS.
12. McFarland W, Kahn JG, Katzenstein DA, Mvere D, Shamu R. 1995. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 9: 183-92.
13. Laleman G, Magazani K, Perriens JH et al. 1992. Prevention of blood-borne HIV transmission using a decentralized approach in Shaba, Zaire. AIDS 6: 1353-8.
14. Spielberg FA, Kabeya CM, Quinn TC et al. 1990. Performance and cost-effectiveness of a dual rapid assay system for screening and confirmation of human immunodeficiency virus type 1 seropositivity. Journal of Clinical Microbiology 28: 303-6.
15. Foster S, Buve A. 1995. Benefits of HIV screening of blood transfusions in Zambia. The Lancet 346: 225-7.
16. Jacobs B, Mercer A. 1999. Feasibility of hospital-based blood banking: a Tanzanian case study. Health Policy and Planning 14: 354-62.
17. Over M, Piot P. 1993. HIV infection and sexually transmitted diseases. In: Jamison D, Mosley WH, Measham AR, Bobadilla JL (eds). Disease control priorities in developing countries. Oxford: Oxford University Press, pp. 455-527.
18. Watson Williams EJ, Kataaha PK. 1990. Revival of the Ugandan Blood Transfusion System 1989: an example of international cooperation. Transfusion Science 11: 179-84.
19. Watson-Williams EJ, Fournel JJ, Sondag D, Fransen L. 1992. Annex 8: EEC's safe blood programme policies and strategies in view of controlling AIDS in developing countries. In: Beal RW, Bontinck M, Fransen L (eds). Safe blood in developing countries: a Report of the EEC's Expert Meeting. Brussels: EEC AIDS Task Force.
20. Evian CR, De Beer M, Crewe M, Padayachee GN, Hurwitz HS. 1991. Evaluation of an AIDS awareness campaign using city buses in Johannesburg. South African Medical Journal 80: 343-6.
21. UNAIDS. Safe sex, my choice (Russian Federation), http://www. unaids/unaids/bpc/summary/cp/safesex.html (accessed on 9/23/ 99).
22. World Bank. 1999. Project appraisal document on a proposed credit in the amount of SDR 140.82 million to India for second national HIV/AIDS control project; 1999. Report No: 18918-IN. Washington DC: The World Bank.
23. Kumaranayake L, del Amo J. 1997. Resource allocation for HIV prevention: cost, epidemiological and behavioural analysis - HIV/AIDS education in schools. London School of Hygiene and Tropical Medicine.
24. Meerding WJ, Meester EI, Korenromp EJ, Habbema JDF. 1999. Cost-effectiveness of HIV interventions in developing countries. Presented at the 2nd International Health Economics Association; Rotterdam.
25. Stallworthy G, Meekers D. 1998. An analysis of unit costs in selected condom social marketing programs, 1990-1996. Population Services International.
26. Hanson K, Kumaranayake L, Thomas I. 1998. Supplying subsidised contraceptives: economic rationale and programme issues for promoting sustainability. London: OPTIONS/DFID.
27. Grosskurth H, Mosha F, Todd J et al. 1995. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. The Lancet 346: 530-6.
28. Gilson L, Mkanje R, Grosskurth H et al. 1997. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. The Lancet 350: 1805-9.
29. Moses S, Plummer FA, Ngugi EN, Nagelkerke NJ, Anzala AO, Ndinya Achola JO. 1991. Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS 5: 407-11.
30. Kumaranayake L, Mangtani PB-KA, Foumena Abada JC, Cheta C, Njoumemi Z, Watts CH. 1998. Cost-effectiveness of a HIV/AIDS peer education programme among commercial sex workers: results from Cameroon. XII International Conference on AIDS. Geneva, July 1998 [abstract 578/33592].
31. Ball A, Rana S, Dehne K. 1998. HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Reports 113 (Suppl 1): 170-81.
32. Needle R, Coyle S, Norman J, Lambert E, Cesari H. 1998. HIV prevention with drug-using populations - current status and future prospects: introduction and overview. Public Health Reports 113 (Suppl 1): 4-30.
33. Walker D, Kumaranayake L, Romantsov V, Samoshkin S, Zviagin V. 2003. What does it cost? An economic analysis of a harm reduction intervention in Svetlogorsk, Belarus. Drugs: Education, Prevention and Policy 8: 385-95.
34. Vickerman P, Watts C. 2002. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. International Journal of Drug Policy 13: 149-64.
35. Kumaranayake L, Watts C, Vickerman P et al. 2000. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. UNAIDS Best Practice Collection. Geneva: UNAIDS.
36. Aisu T, Raviglione MC, van Praag E et al. 1995. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 9: 267-73.
37. Sweat M, Gregorich S, Sangiwa G et al. 2000. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. The Lancet 356: 113-21.
38. Mansergh G, Haddix AC, Steketee RW et al. 1996. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. Journal of the American Medical Association 276: 139-45.
39. Marseille E, Kahn JG, Saba J. 1998. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 12: 939-48.
40. Wilkinson D, Floyd K, Gilks CF. 1998. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 12: 1675-82.
41. Soderlund N, Zwi K, Kinghorn A, Gray G. 1999. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. British Medical Journal 318: 1650-6.
42. Marseille E, Kahn JG, Mmiro F et al. 1999. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. The Lancet 354: 803-9.
43. Stringer J, Rouse DJ, Vermund SH, Goldenburg RL, Sinkala M, Stinett AA. 2000. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes 24: 369-77.
44. Prescott N. 1997. Setting priorities for government involvement with antiretrovirals. In: Katz AM, Praag EV (eds). The implications of antiretroviral treatments: informal consultation. Geneva: WHO, pp. 57-62.
45. Walker D. 1997. Reducing perinatal transmission of HIV in Thailand: A cost-effectiveness analysis of the treatment with AZT of HIV-infected pregnant women in Thailand. Presented at the Ghent International Working Group on Mother to Child Transmission; London.
46. Kumar M. 2000. Cost-effectiveness of prevention of mother-to-child HIV transmission in Kerala, India. Presented at the International AIDS Economic Network Symposium July 7-8, 2000; Durban, South Africa.
47. Lallemant M, Le Coeur S, Shepard D, Marlink R. 1996. Preventing perinatal HIV transmission in developing countries: a cost- effectiveness perspective. XI International Conference on AIDS. Vancouver, September 1996 [abstract Th.C.4822].
48. Elias CJ, Coggins C. 1996. Female-controlled methods to prevent sexual transmission of HIV. AIDS 10 (Suppl 3): 543-51.
49. Elias CJ, Heise L. 1993. The development of microbicides: a new method of HIV prevention for women. Population Council Working Paper.
50. Elias CJ, Heise LL. 1994. Challenges for the development of female-controlled vaginal microbicides. AIDS 8: 1-9.
51. Marseille E, Kahn J, Billinghurst K, Saba J. 2001. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. Social Science and Medicine 52: 135-48.
52. Homan RK, Visness C, Welsh M, Schwingl P. 1999. Estimated HIV prevention and costs for female condom introduction program in alternative target audiences. Report prepared for Family Health International.
53. Cowley P. 1993. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast. Health Policy 24: 145-53.
54. Bishai D, Lin M, Kiyonga C. 2000. Algorithms for purchasing AIDS vaccines. Presented at the International AIDS Economic Network Symposium July 7-8, 2000; Durban, South Africa.
55. Tangcharoensathien VPW, Pitayarangsarit S, Kongsin S, Kasemsup V, Tantivess S, Suraratdecha C. 2000. The potential demand for an AIDS vaccine in Thailand. Presented at the International AIDS Economic Network Symposium July 7-8, 2000; Durban, South Africa.
56. Mumford E, Dayaratna V, Winfrey W, Sine J, McGreevey W. 1998. Reproductive health costs literature review. The Policy Project.
57. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. 2000. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trial. The Lancet 355: WA8-14.
58. Brenzel L, Claquin P. 1994. Immunization programs and their costs. Social Science and Medicine 39: 527-36.
59. Dunlop DW. 1984. Theoretical and empirical issues in benefit identification, measurement and valuation related to parasitic disease control in poor countries. Social Science and Medicine 19: 1031-7.
60. Walker D, Fox-Rushby J. 2000. Economic evaluation of parasitic diseases: a critique of the internal and external validity of published studies. Tropical Medicine and International Health 5: 237-49.
61. Walker D, Fox-Rushby J. 2000. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Economics 9: 681-98.
62. Phillips MA, Feachem RG, Mills A. 1987. Options for diarrhoea control: the cost and cost-effectiveness of selected interventions for the prevention of diarrhoea. London School of Hygiene and Tropical Medicine, Evaluation and Planning Centre for Health Care.
63. Jamison D, Mosley W, Measham A, Bobadilla J. 1993. Disease control priorities in developing countries. New York: Oxford University Press.
64. Fryatt RJ. 1997. Review of published cost-effectiveness studies on tuberculosis treatment programmes. International Journal of Tuberculosis and Lung Disease 1: 101-9.
65. Newell ML, Dabis F, Tolley K, Whynes D. 1998. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV. AIDS 12: 1571-80.
66. Janowitz B, Bratt JH. 1992. Costs of family planning services: a critique of the literature. International Family Planning Perspectives 18: 137-44.
67. Walker D. 2001. How to do (or not to do) ... Cost and cost-effectiveness guidelines: which ones to use? Health Policy and Planning 16: 113-21.
68. Barberis M, Harvey PD. 1997. Costs of family planning programmes in fourteen developing countries by method of service delivery. Journal of Biosocial Science 29: 219-33.
69. Anonymous. 1985. Cost/CYP: a bottom line that helps keep CSM projects cost-efficient. Social Marketing Reform 2: 4-5.
70. Shelton D. 1991. What's wrong with CYP? Studies in Family Planning 22: 332-5.
71. Watts C, Kumaranayake L, Vickerman P. 1999. HIVTools: A toolkit to estimate the impact and cost-effectiveness of HIV prevention strategies. XI International Conference on AIDs and STDs in Africa. Lusaka. September 1999 [abstract 13PT21-8].
72. Anand S, Hanson K. 1997. Disability-adjusted life years: a critical review. Journal of Health Economics 16: 685-702.
73. Barker C, Green A. 1996. Opening the debate on DALYs. Health Policy and Planning 11: 179-83.
74. Morrow RH, Bryant JH. 1995. Health policy approaches to measuring and valuing human life: conceptual and ethical issues. American Journal of Public Health 85: 1356-60.
75. Murray C, Evans D, Acharya A, Baltussen R. 2000. Development of WHO guidelines on generalised cost-effectiveness analysis. Health Economics 9: 235-51.
76. World Bank. 1993. World Development Report 1993: Investing in Health. Oxford: Oxford University Press.